

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
9 December 2004 (09.12.2004)

PCT

(10) International Publication Number  
WO 2004/106488 A2

(51) International Patent Classification<sup>7</sup>: C12N

(21) International Application Number:  
PCT/US2003/014631

(22) International Filing Date: 12 May 2003 (12.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): POTOMAC PHARMACEUTICALS, INC. [US/US];  
11713 Tifton Drive, Potomac, MD 20854 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): YINGXIAN, Xiao [US/US]; 11713 Tifton Drive, Potomac, MD 20854 (US).  
XIN-HUA, Feng [CN/US]; 3119 Plumb Street, Houston, TX 77005 (US).

(74) Agent: MOGA, Thomas, T.; Dickinson Wright PLLC,  
1901 L Street NW, Suite 800, Washington, DC 20036 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to the identity of the inventor (Rule 4.17(i)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA.

[Continued on next page]

(54) Title: GENE EXPRESSION SUPPRESSION AGENTS



siRNA Template

(57) Abstract: A method is provided for making gene suppression agents to be used in eukaryotic cells by using a recombinant DNA construct containing at least one transcriptional unit comprising a transcriptional promoter, a template sequence for making a RNA molecule, and a transcriptional terminator. Mechanisms of the RNA mediated gene suppression include, but not limited to, RNA interferences (RNAi). The use of the agents as tools for biomedical research as well as medicinal products is also disclosed.

WO 2004/106488 A2



UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

3/PC  
JC20 Rec'd PCT/PTO 13 OCT 2005  
GENE EXPRESSION SUPPRESSION AGENTS**RELATED APPLICATION**

This application claims the benefit of priority of provisional application No. 60/377,964 filed May 7, 2002.

**BACKGROUND OF THE INVENTION****1. Technical Field**

The present invention relates to medicine and biomedical research. More specifically, the present invention relates to expression systems to produce small hairpin RNAs (shRNAs) or interfering RNAs (siRNAs), collectively called siRNA in this application, in eukaryotic cells and methods for expressing siRNAs in eukaryotic cells. The present invention also relates to the use of the expression systems as medicinal products.

**2. Related Art**

RNA interference (RNAi) is a process of sequence-specific, post-transcriptional gene silencing (PTGS) in animals and plants initiated by double-stranded RNA (dsRNA) that is homologous to the silenced gene. It is an evolutionarily conserved phenomenon and a multi-step process that involves generations of active siRNAs in vivo through the action of a mechanism that is not fully understood. RNAi has been used as a reverse genetic tool to study gene function in multiple model organisms, such as plants, *Caenorhabditis elegans* and *Drosophila*, where large dsRNAs efficiently induce gene-specific silencing.

In mammalian cells dsRNAs, 30 base pairs or longer, can activate antiviral response, leading to the nonspecific degradation of RNA transcripts and a general shutdown of host cell protein translation. As a result, the long dsRNA is not a general method for silencing specific genes in mammalian cells.

Recently, various siRNAs that were synthesized chemically or generated biologically using DNA templates and RNA polymerases have been used to down regulate expression of targeted genes in cultured mammalian cells. Among approaches used, it is highly desirable to use DNA constructs that contain promoters of transcriptions and templates for siRNAs to generate siRNAs in vivo and in vitro. Though several different promoters have been adapted in such DNA constructs, types of promoters used remain limited to, Type III RNA polymerase III (Pol III) promoters, such as the U6 promoter and the H1 promoter, and promoters that require viral RNA polymerases, such as the T7 promoter. The present invention provides methods and designs to produce gene expression suppression agents that greatly expand potential usages of siRNAs.

#### **SUMMARY OF THE INVENTION**

The present invention relates to methods to produce gene expression suppression agents for expression of siRNAs in mammalian cells. Such agents contain RNA polymerase III (Pol III) transcription promoter elements, template sequences for siRNAs, which are to be transcribed in host cells, and a terminator sequence.

The promoter is any native or engineered transcription promoter. As examples of such promoters (not intended on being limiting), in one embodiment, the promoter is a Type I Pol III promoter, while in another embodiment, the promoter is a combination of Type I Pol III promoter elements and Type III Pol III promoter elements. In other embodiments other types of promoters are present.

The targeted region of siRNA is anywhere on a transcript of any sequence in eukaryotic or viral genomes. The terminator is any native or engineered sequence that terminates the transcription by Pol III or other types of RNA polymerases.

Such gene expression suppression agents are delivered into eukaryotic cells, including (but not limiting to) mammals, insects, worms and plants, with any routes, procedures or methods, such as (but not limited to), in vivo, in vitro, ex vivo, electroporations, transfections or viral vector transduction.

#### BRIEF DESCRIPTION OF THE FIGURES

Fig. 1 is a schematic representation of the embodiment for generating siRNA in mammalian cells using vertebrate Type I Pol III promoters. Specifically, Fig. 1 is a schematic representation of strategy for generating siRNA in mammalian cells using vertebrate Type I Pol III promoters (5S rRNA gene promoter and others). "A Box", "C Box", "D Box" and "IE" are Pol III promoter elements, "+1" is an initiation site of transcription, "Tn" is a termination site of the Pol III promoter transcript, and the arrow indicates the orientation of transcription. The siRNA template consists of sense,

spacer, antisense and terminator sequences, and generates a hairpin dsRNA when expressed. "Sense" is a 17-23 nucleotide (nt) sense sequence that is identical to that of the target gene and is a template of one strand of the stem in the hairpin dsRNA. "Spacer" is a 4-15 nt sequence and is a template of the loop of the strand of the stem in the hairpin dsRNA. "Terminator" is the transcriptional termination signal of five thymidines (5 Ts).

Fig. 2 is a schematic representation of the embodiment for generating siRNA in mammalian cells using vertebrate Type III Pol III promoters (U6 gene promoter, H1 gene promoter, Y1 gene promoter, Y3 gene promoter, RNase P gene promoter and others). DSE, distal sequence element of Pol III promoter; PSE, proximal sequence element of Pol III promoter; TATA, a promoter element; +1, initiation site of transcription; the arrow indicates the orientation of transcription; siRNA Template, a 43 – 66 nt engineered insert that is the template for generating a hairpin dsRNA against a target gene; Sense, a 17 – 23 nt sense sequence from the target gene, template of one strand of stem in the hairpin; Spacer, a 4 – 15 nt sequence, template of loop of the hairpin; Antisense, a 17 – 23 nt antisense sequence, template of the other strand of stem in hairpin; Terminator, the transcriptional termination signal of 5 thymidines (5 Ts).

Fig. 3 is a schematic representation of the embodiment for generating siRNA in mammalian cells using an engineered Pol III promoter containing the elements in both Type I and Type III promoters. "DSE" is a distal sequence element of Type III Pol III promoter. "PSE" is a proximal sequence element of Type III Pol III promoter; "TATA" is

a Type III Pol III promoter element. "A Box," "C Box" and "IE" are Type I Pol III promoter elements. "+1" is an initiation site of transcription. "Tn" is a termination site of the Type III Pol III promoter transcript. The arrow indicates the orientation of transcription. The siRNA template consists of sense, spacer, antisense and terminator sequences, and generates a hairpin dsRNA when expressed. "Sense" is a 17-23 nt sense sequence that is identical to that of the target gene and is a template of one strand of the stem in the hairpin dsRNA. "Spacer" is a 4-15 nt sequence and is a template of the loop of the hairpin dsRNA. "Antisense" is a 17-23 nt antisense sequence and is a template of the other strand of stem in hairpin dsRNA. "Terminator" is the transcriptional termination signal of five thymidines (5 Ts).

Fig. 4 is a schematic representation of the embodiment for generating siRNA in mammalian cells using two vertebrate Type I Pol III promoters that drive transcriptions of sense siRNA and antisense siRNA separately. "A Box," "C Box," "D Box" and "IE" are Pol III promoter elements. "+1" is an initiation site of transcription. "Tn" is a termination site of the Pol III promoter transcript. The arrow indicates the orientation of transcription. "Sense siRNA Template" is a 22-28 nt engineered insert that is the template for generating a sense single-stranded RNA (ssRNA) against a target gene, and consists of sense and terminator sequences. "Antisense siRNA Template" is a 22-28 nt engineered insert that is the template for generating an antisense ssRNA against a target gene, and consists of antisense and terminator sequences. "Sense" is a 17-23 nt sense sequence that is identical to that of the target gene and is a template of one strand of the stem in the hairpin dsRNA. "Spacer" is a 4-15 nt sequence and is a

template of loop of hairpin dsRNA. "Antisense" is a 17-23 nt antisense sequence and is a template of the other strand of the stem in the hairpin dsRNA. "Terminator" is the transcriptional termination signal of five thymidines (5 Ts).

Fig. 5 is a schematic representation of the embodiment for generating siRNA in mammalian cells using an engineered T7 polymerase and T7 promoter. "Promoter" is a constitutive or context-dependent promoter such as an inducible promoter or a cell type specific promoter; "T7 Polymerase Gene" is a sequence coding for T7 polymerase. "T7 promoter" is a T7 promoter. "+1" is an initiation site of transcription. The arrow indicates the orientation of transcription. The siRNA template consists of sense, spacer, antisense and terminator sequences, and generates a hairpin dsRNA when expressed. "Sense" is a 17-23 nt sense sequence that is identical to that of the target gene and is a template of one strand of the stem in the hairpin dsRNA. "Spacer" is a 4-15 nt sequence and is a template of the loop of the hairpin dsRNA. "Antisense" is a 17-23 nt antisense sequence and is a template of the other strand of stem in the hairpin dsRNA. "Terminator" is an engineered terminator for T7 polymerase.

Fig. 6 is a schematic representation of the embodiment for generating multiple siRNAs in mammalian cells using a single multiple transcription unit construct. "Unit" is a transcription unit that contains a vertebrate Type I Pol III promoter and a siRNA template. "A Box", "C Box", "D Box" and "IE" are Pol III promoter elements. "+1" is an initiation site of transcription. "Tn" is a termination site of the Pol III promoter transcript. The arrow indicates the orientation of transcription. The structure of siRNA template



consists of sense, spacer, antisense and terminator sequences, and is an engineered insert that is the template for generating a hairpin dsRNA against a target gene.

"Sense" is a 17-23 nucleotide (nt) sense sequence that is identical to that of the target gene and is a template of one strand of the stem in the hairpin dsRNA. "Spacer" is a 4-15 nt sequence and is a template of the loop of the hairpin dsRNA. "Antisense" is a 17-23 nt antisense sequence and is a template of the other strand of stem in hairpin dsRNA. "Terminator" is the transcriptional termination signal of five thymidines (5 Ts). The multiple siRNAs may target a single region on one gene, different regions on one gene, or one region on each of many genes.

#### **DETAILED DESCRIPTION OF THE INVENTION**

The following detailed description is provided to aid those skilled in the art to use the present invention. It should not be viewed as defining limitations of this invention.

The present invention is directed to selectively suppress expression of genes targeted within mammalian cells by making and using DNA constructs that contains RNA polymerase III (Pol III) transcription promoter elements, template sequences for siRNAs, which are to be transcribed in host cells, and a terminator sequence.

The promoter is any native or engineered transcription promoter. In one embodiment, the promoter is a Type I Pol III promoter. The essential elements of Type I promoter, such as "A Box", "C Box", "D Box" and "IE" are included in the DNA construct. In this embodiment, siRNA template is arranged between the "D Box" and "A Box". As in

another embodiment, the promoter is a combination of Type I Pol III promoter elements and Type III Pol III promoter elements. In this embodiment, the essential elements of both types of promoters, such as "A Box", "C Box", and "IE" of Type I promoter, as well as "DSE", "PSE" and "TATA" of Type III promoter are included in the DNA construct, with "DSE", "PSE" and "TATA" in the upstream region of "+1" position, "A Box", "C Box", and "IE" in the down stream region of the "+1" position. Any promoter that is functioned in the mammalian cells is suitable to be used in this invention. Modifications, such as adding inducible or enhancing elements to exiting promoters, is suitable to be used in this invention.

The targeted region of siRNA is anywhere on a transcript of any sequence in mammalian or viral genomes. In some embodiments, templates for siRNA code for RNA molecules with "hairpin" structures contains both sense and antisense sequences of targeted genes. In other embodiments, the template for sense sequence and the template for antisense sequences are driven by different promoters.

The terminator is any native or engineered sequence that terminates the transcription by Pol III or other types of RNA polymerases, such as, without limited to, a stretch of 4 or more thymidines (T) residues in a DNA molecule.

Any transcriptional unit containing a promoter, a template for RNA and a terminator, is suitable to be constructed with one other unit, or multiple units, in a DNA molecule as an agent. In one embodiment, a multiple units construct is showed. More than one kind of

the gene expression suppression agents (DNA molecules) are suitable to be introduced into mammalian cells together. The siRNAs generated within the same mammalian cell by these multiple units or co-introduction approaches provide agents ability to target one specific region in one targeted RNA molecule, multiple regions in one targeted RNA molecule, or multiple regions in more than one RNA molecules.

Such DNA constructs as indicated above can be constructed as a part of any suitable cloning vectors or expression vectors. Then the agents can be delivered into cells, tissues or organisms with any routes, procedures or methods, such as *in vivo*, *in vitro*, *ex vivo*, injection, electroporations, transfections or viral vector transduction.

## EXAMPLES

### Example 1

Cloning of the human 5S rDNA regulatory sequences.

The promoter chosen for the experimental design proposed below is the human 5S rRNA gene. The sequence is available in the database: Genbank Accession Number X12811. 5S rRNA promoter contains downstream Boxes A and C and upstream Box D.

In Fig. 1, the 49 nt sequence between the initiation site of the 5S rRNA and Box A is proposed to be replaced with interfering RNA sequence. Generation of a cassette containing both upstream and downstream boxes will be carried out in two steps.

Cloning of the Box A and C can be achieved by chemical synthesis. The upstream Box D is done by PCR.

Cloning of the recombinant 5S rDNA Box D is carried out through PCR using forward primer (AACg gatccaaaacgctgcctccgcga) and reverse primer (TAGACGCTGCAGGAGGCGCCTGGCT, which can then be subcloned into BamHI and PstI sites of pBS2SK. The Box A/C can be synthesized as top strand (AGAAGACGAagctaagcagggtcgggcctggtagtacttgatgggagaccgcctgggaataccgggtgctgtaggcttttg) and bottom strand (TCGACAAAAAGCCTACAGCACCCGGTATTCCCAGGCGGTCTCCCATCCAAGTACTAACCAGGCCCGACCCTGCTTAGCTTCGTCTTCT), which are then annealed and subcloned into EcoRV and Sall sites downstream of the cloned Box D. The annealed DNA fragment is engineered with a BbsI site.

### Example 2

Insertion and Cloning of RNAi Sequence.

The RNAi cassette will be synthesized as two strands and cloned between PstI and BbsI site. The RNAi cassette is designed as follows:

5' GC(N19)TTTCGG(61N)TTTTT 3'  
3' ACGTCG(61N)AAAGCC(N19)AAAAATCGA 5'

N19 is the 19 nt target DNA sequence selected from the transcribed region of a target gene. 61N is the reverse and complementary strand of N19. Transcription is initiated from the first base of N19 target sequence and terminated at the poly T.

### Example 3

Targeting ErbB2/Her2 in breast cancers.

ErbB2/Her2 gene is amplified in ~30% of breast cancers in human, causing fast growth and metastasis of cancer cells. Herceptin, an antibody made by Genentech that blocks ErbB2 functions, is the only agent used by ErbB2-positive breast cancer patients that slows progression of metastatic breast disease and increases overall survival for patients given the drug along with standard chemotherapy compared to chemotherapy alone. Generation of siRNAs targeting ErbB2 developed with this invention should provide an alternative treatment.

#### **Example 4**

Targeting BCR-Abl tyrosine kinase in chronic myelogenous leukemia (CML) and other cancers. BCR-Abl is a fusion gene product that frequently occurs in CML. STI571, also called Gleevec developed by Novartis, is newly approved anticancer agent to target BCR-Abl in CML. Generation of siRNAs against the fusion gene BCR-Abl, without interfering with the normal expression of either BCR or Abl gene, developed with this invention should have great potential for gene therapy to treat CML.

#### **Example 5**

Targeting Hepatitis B Virus (HBV).

Using this invention to target different sites of the HBV genome will provide a potent gene therapy to treat hepatitis B infected patients.

#### **Example 6**

Targeting Human Immunodeficiency Virus Type 1 (HIV-1).

Using this invention to target different sites of the HIV genome will provide a potent gene therapy for HIV infected patients. A multiple units agent simultaneously targeting multiple sites, such as env, gag, pol, vif, nef, vpr, vpu and tat, may be suitable to address resistances resulted from mutations of HIV genome.

**CLAIMS**



*We claim:*

1. A recombinant DNA construct containing at least one transcriptional unit comprising a transcriptional promoter, a template sequence for making an RNA molecule, and a transcriptional terminator.
2. The construct of Claim 1, wherein a native Type I Pol III promoter is the initiating mechanism for transcription.
3. The construct of Claim 1, wherein an engineered Type I Pol III promoter is the initiating mechanism for transcription.
4. The construct of Claim 1, wherein a native promoter containing one or more essential elements of the Type I Pol III promoter is the initiating mechanism for transcription.
5. The construct of Claim 1, wherein an engineered promoter containing one or more essential elements of the Type I Pol III promoter is the initiating mechanism for transcription.
6. The construct of Claim 1, wherein a native promoter, which may initiate transcription by any mammalian or viral RNA polymerases, is the initiating mechanism for transcription.



7. The construct of Claim 1, wherein an engineered promoter, which may initiate transcription by any mammalian or viral RNA polymerases, is the initiating mechanism for transcription.
8. The construct of Claim 1, wherein said template compromising sequence for generating a full, or a part of, RNA molecule which will down regulate expression of a target gene through RNA mediate down regulation, including but not limited to RNAi.
9. The construct of Claim 8 wherein the target gene is a gene selected from the group consisting of the mammalian and viral genomes.
10. The construct of Claim 1, wherein said transcriptional unit is constructed with more than one other such transcriptional units in the same DNA molecule to target same or different region of a gene or genes.
11. A cloning or expression vector that contains the construct of Claim 1.
12. Molecules, cells, tissues, organs, organisms, or any other materials engineered, that contains the construct of Claim 1.
13. The construct of Claim 1, wherein said template compromises a sequence for generating a full or part of, RNA molecule which may bind its targets (e.g. DNA, RNA, proteins or any other forms of molecules) and regulate functions of these targets.
14. A method for making a gene suppression agent to be used in a eukaryotic cell, the method including use of a recombinant DNA construct containing at least one transcriptional unit compromising a transcriptional promoter, a template sequence for making a RNA molecule, and a transcriptional terminator.




1/3

**Figure 1****Figure 2**


2/3

**Figure 3****Figure 4**

3/3



siRNA Template

**Figure 5**

siRNA Template

**Figure 6**